Galmed Pharmaceuticals Ltd.
(NASDAQ : GLMD)

( )
GLMD PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
MDCOThe Medicines Co.
-0.05%84.0320.1%$620.21m
AMRNAmarin Corp. Plc
0.65%23.141.7%$276.77m
VRXValeant Pharmaceuticals International, Inc.
8.71%31.8914.1%$187.65m
ARQLArQule, Inc.
-1.04%19.990.6%$140.34m
SAGESAGE Therapeutics, Inc.
4.70%76.008.6%$135.29m
BHCBausch Health Cos., Inc.
8.71%31.890.0%$132.19m
ICPTIntercept Pharmaceuticals, Inc.
-2.87%115.9316.9%$94.12m
JAZZJazz Pharmaceuticals Plc
1.20%149.902.3%$91.82m
GWPHGW Pharmaceuticals Plc
2.74%105.706.2%$86.29m
PRGOPerrigo Co. Plc
1.36%54.546.8%$65.30m
AXSMAxsome Therapeutics, Inc.
1.04%48.572.0%$60.26m
HZNPHorizon Therapeutics Plc
1.83%32.846.6%$44.72m
ICLRICON plc
-0.10%161.574.2%$42.46m
UTHRUnited Therapeutics Corp.
1.37%93.7614.3%$36.17m
ENDPEndo International Plc
7.06%4.708.8%$33.53m

Company Profile

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on the development of the liver targeted stearoyl-coenzyme A desaturase-1 modulator Aramchol, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders. The Aramchol is a synthetic conjugate of cholic acid, or a type of bile acid, and arachidic acid, or a type of saturated fatty acid, both of which, in their non-synthetic forms, are naturally occurring. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.